Discovery of novel anxiolytic agents - The trials and tribulations of pre-clinical models of anxiety

Neurobiology of Disease

Volumn 61, Issue , 2014, Pages 72-78

  Andrews, N A ^a   Papakosta, M ^b   Barnes, N M ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anxiety; Behavior; Pre clinical models

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; FLUOXETINE; IMIPRAMINE; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; AVOIDANCE BEHAVIOR; CONDITIONING; CONFLICT; CONSTRUCT VALIDITY; DEPRESSION; ELECTRIC SHOCK; EXPERIMENTAL TEST; FEAR; FOOD DEPRIVATION; GABAERGIC SYSTEM; HUMAN; MAZE TEST; NEOPHOBIA; NONHUMAN; OPEN FIELD TEST; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SOCIAL INTERACTION; SOCIAL PHOBIA; WATER DEPRIVATION;

ANXIETY; BEHAVIOR; PRE-CLINICAL MODELS;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; MICE; RATS;

EID: 84888051360     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.006     Document Type: Review

References (50)

1. Andrews N., File S.E. Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology (Berl.) 1993, 112:21-25.
2. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 1993, 235:109-112.
3. Aron C., Simon P., Larousse C., Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1971, 10:459-469.
4. Barrett J.E., Witkin J.M., Mansbach R.S., Skolnick P., Weissman B.A. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J. Pharmacol. Exp. Ther. 1986, 238:1009-1013.
5. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 1997, 21:783-789.
6. Blanchard D.C., Griebel G., Blanchard R.J. Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci. Biobehav. Rev. 2001, 25:205-218.
7. Bourin M., Hascoët M. The mouse light/dark box test. Eur. J. Pharmacol. 2003, 463:55-65.
8. Chaouloff F., Castanon N., Mormède P. Paradoxical differences in animal models of anxiety among the Roman rat lines. Neurosci. Lett. 1994, 182:217-221.
9. Choleris E., Thomas A.W., Kavaliers M., Prato F.S. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci. Biobehav. Rev. 2001, 25:235-260.
10. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 1980, 13:167-170.
11. Cryan J.F., Sweeney F.F. The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br. J. Pharmacol. 2011, 164:1129-1161.
12. Davis M. Pharmacological analysis of fear-potentiated startle. Braz. J. Med. Biol. Res. 1993, 26:235-260.
13. Deacon R.M. Hyponeophagia: a measure of anxiety in the mouse. J. Vis. Exp. 2011, 17(51).
14. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 1990, 100:281-282.
15. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 2001, 125:151-157.
16. File S.E., Andrews N. Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes. Biochem. Soc. Symp. 1993, 59:97-106.
17. File S.E., Hyde J.R. Can social interaction be used to measure anxiety?. Br. J. Pharmacol. 1978, 62:19-24.
18. File S.E., Hyde J.R. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol. Biochem. Behav. 1979, 11:65-69.
19. File S.E., Seth P. A review of 25years of the social interaction test. Eur. J. Pharmacol. 2003, 463:35-53.
20. File S.E., Gonzalez L.E., Andrews N. Comparative study of pre- and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci. 1996, 16:4810-4815.
21. Geller I., Seifter J. The effects of meprobamate, barbiturate, Damphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1960, 1:482-492.
22. George S.A., Hutson P.H., Stephens D.N. Differential effects of MPEP and diazepam in tests of conditioned emotional response and Pavlovian-to-instrumental transfer suggests 'anxiolytic' effects are mediated by different mechanisms. Psychopharmacology (Berl.) 2009, 204:499-509.
23. Graeff F.G., Netto C.F., Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 1998, 23:237-246.
24. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 1984, 327:1-5.
25. Hascoet M., Bourin M. Mood and Anxiety Related Phenotypes in Mice. Neuromethods 2011, vol. 63:123-141.
26. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 1996, 54:21-30.
27. Holmdahl R., Malissen B. The need for littermate controls. Eur. J. Immunol. 2012, 42:45-47.
28. Kessler R.C., Aguilar-Gaxiola S., Alonso J., Chatterji S., Lee S., Ormel J., Ustün T.B., Wang P.S. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol. Psichiatr. Soc. 2009, 18:23-33.
29. Kilkenny C., Browne W., Cuthill I.C., Emerson M., Altman D.G. NC3Rs reporting guidelines working group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. J. Gene Med. 2010, 12:561-563.
30. Kim M.J., Loucks R.A., Palmer A.L., Brown A.C., Solomon K.M., Marchante A.N., Whalen P.J. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav. Brain Res. 2011, 223:403-410.
31. Knapp D.J., Sim-Selley L.J., Breese G.R., Overstreet D.H. Selective breeding of 5-HT(1A) receptor-mediated responses: application to emotion and receptor action. Pharmacol. Biochem. Behav. 2000, 67:701-708.
32. Komada M., Takao K., Miyakawa T. Elevated plus maze for mice. J. Vis. Exp. 2008, 22.
33. Lissek S. Toward an account of clinical anxiety predicated on basic, neurally mapped mechanisms of Pavlovian fear-learning: the case for conditioned overgeneralization. Depress. Anxiety 2012, 29:257-263.
34. Maren S., Phan K.L., Liberzon I. The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 2013, 14:417-428.
35. McLean C.P., Asnaani A., Litz B.T., Hofmann S.G. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J. Psychiatr. Res. 2011.
36. Merali Z., Bédard T., Andrews N., Davis B., McKnight A.T., Gonzalez M.I., Pritchard M., Kent P., Anisman H. Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J. Neurosci. 2006, 26:10387-10396.
37. Mountney C., Anisman H., Merali Z. Effects of gastrin-releasing peptide agonist and antagonist administered to the basolateral nucleus of the amygdala on conditioned fear in the rat. Psychopharmacology (Berl.) 2008, 200:51-58.
38. O'Tuathaigh C.M., Babovic D., O'Meara G., Clifford J.J., Croke D.T., Waddington J.L. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci. Biobehav. Rev. 2007, 31:60-78.
39. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
40. Pinel J.P.J., Treit D. Burying as a defensive response in rats. J. Comp. Physiol. Psychol. 1978, 92:708-712.
41. Rodgers R. Animal Tests for Anxiety. Encyclopedia of Behavioral Neuroscience 2010, 90-100. Academic Press, Oxford. G.F. Koob, M. Le Moal, R.F. Thompson (Eds.).
42. Rodgers R.J., Cao B.J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 1997, 30:289-304.
43. Rodgers R.J., Haller J., Halasz J., Mikics E. One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 2003, 17:1279-1286.
44. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J. Neurosci. Methods 1995, 59:157-167.
45. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 1994, 116:56-64.
46. Takao K., Miyakawa T. Light/dark transition test for mice. J. Vis. Exp. 2006, 13:104.
47. Teixeira R.C., Zangrossi-Jr H., Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 2000, 65:571-576.
48. Treit D., Pinel J.P., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 1981, 15:619-626.
49. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971, 21:1-7.
50. Zangrossi H., File S.E. Behavioral consequences in animal tests of anxiety and exploration of exposure to cat odor. Brain Res. Bull. 1992, 29:381-388.